Aprepitant Injection

DRUG4 trials

Sponsors

Sichuan Cancer Hospital and Research Institute, CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd., Qilu Pharmaceutical (Hainan) Co., Ltd., Endeavor Health

Conditions

Cervical CancerEndometrial CancerFallopian Tube CancerGynecological TumorOvarian CancerPONVPost-operative Nausea and Vomiting (PONV)Postoperative Nausea and Vomiting

Phase 3

Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients

CompletedNCT06007586

Sichuan Cancer Hospital and Research InstituteCervical Cancer, Endometrial Cancer, Fallopian Tube Cancer +2

Start: 2024-05-31End: 2025-07-04Updated: 2025-12-04

Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting

Not yet recruitingNCT06543966

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Post-operative Nausea and Vomiting (PONV)

Start: 2024-10-28End: 2026-03-28Target: 486Updated: 2024-08-09

Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting

CompletedNCT06932107

Qilu Pharmaceutical (Hainan) Co., Ltd.Postoperative Nausea and Vomiting

Start: 2024-02-02End: 2024-06-05Updated: 2025-04-23

Phase 4

Aprepitant to Improve Same Day Discharge for TKA

Not yet recruitingNCT07639723

Endeavor HealthPONV

Start: 2026-07-01End: 2027-08-01Target: 350Updated: 2026-06-10